PCN280 - IMPACT OF SUBOPTIMAL CLINICAL EVIDENCE ON HEALTH TECHNOLOGY ASSESSMENT RECOMMENDATIONS

To assess the impact of suboptimal clinical evidence on funding recommendations. Using published pan-Canadian Oncology Drug Review (pCODR) reports, 111 unique decisions spanning July 2011 to April 2018 were identified. Thirty-nine independent variables were consistently reported covering clinical, economic, and patient inputs. Quality of trials providing clinical evidence was measured regarding randomization, phase, design (non-inferiority vs....